

Substitute for form 1449A/PTO
**ELEVENTH INFORMATION
DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A(08-03)
Approved for use through 07/31/2008. OMB 0651-0031
US Patent & Trademark Office, U.S. DEPARTMENT OF COMMERCE

Complete if Known

U.S. Application No.	10/042,644
Filing or 371(c) date	January 8, 2002
First Named Inventor	Jacques F. BANCHEREAU
Group Art Unit	1646
Examiner Name	Gyan Chandra

Sheet 1 of 1

Attorney Docket No: 13786-7

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document
--------------------	---------------------	------------------	---

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Abstract, Translation, English Language Equivalent or Search Report
--------------------	---------------------	------------------	---	---

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Abstract, Translation, English Language Equivalent or Search Report
	Bennett et al., "Interferon and granulopoiesis signatures in systemic lupus erythematosus blood", J. Exp. Med., 197:711-723 (2003)	
	KAWADE and WATANABE, "The nature of neutralization reaction between effector protein and monoclonal antibody: a quantitative study of neutralization characteristics of anti-interferon antibodies", Immunology 56:489-495 (1985)	
	KONTSEK et al., "Enhancement of neutralizing efficacy by combining three monoclonal antibodies to human interferon-alpha", Immunology, 73:8-11 (1991)	
	Mathian et al., "IFN-alpha induces lethal lupus in young, pre-autoimmune (New Zealand Black x New Zealand White) FE but not in BALB/c mice", J. Immunol., 174: 2499-2506 (2004)	
	MEAGER, A., "Natural autoantibodies to interferons", J. Interferon Cytokine Res., 17 Suppl. 1:S51-53 (1997)	
	PAQUETTE et al., "Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells", J. Leukocyte Biology 64: 358-367, September 1998.	
	Pascual et al., "The central role of dendritic cells and interferon-alpha in SLE", Curr. Opin. Rheumatol, 15:548-556 (2003)	
	PREBLE et al., "Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon", Science, 216:429-431 (1982)	
	RAANANI et al., "Immune-mediated complications during interferon therapy in hematological patients", Acta Haematol, 107:133-144 (2002)	
	SANTINI et al., "Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in hu-PBL-SCID mice", J. Exp Med 191 (10): 1777-1788, May 15, 2000.	
	SHEARER et al., "Monoclonal antibodies that distinguish between subspecies of human interferon-alpha and that detect interferon oligomers", J. Immunol., 133:3096-3101 (1984)	
	WEBER et al. "Single amino acid changes that render human IFN-alpha 2 biologically active on mouse cells", EMBO J., 6:591-198 (1987)	

604293v1

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached